Alvesco (ciclesonide) is prescribed in a fairly narrow dose range for asthma, typically 80 to 320 micrograms per day for adults and 40 to 160 micrograms per day for children, taken once daily. What makes Alvesco unusual among inhaled corticosteroids is that it is a prodrug, meaning the medication you inhale is not the active drug itself. Enzymes in your lungs convert it into the compound that actually fights inflammation, which shapes both how it is dosed and why its side-effect profile differs from older inhalers.
Standard Adult Doses
For adults and adolescents aged 12 and older, Alvesco is available in two metered-dose inhaler strengths: 80 mcg per puff and 160 mcg per puff. The recommended starting dose depends on how severe your asthma is and what you were taking before. If you were previously using a bronchodilator alone without any steroid inhaler, a typical starting dose is 80 mcg once daily. If you were already on another inhaled corticosteroid, 160 mcg once daily is common. And if you were on oral corticosteroids, prescribers sometimes start at 320 mcg twice daily (640 mcg total), though this is at the upper end of the labeled range.
A key feature of Alvesco dosing is that once-daily administration works for most patients. In a 12-week trial of adults with mild-to-moderate persistent asthma, doses of 80, 160, and 320 mcg once daily all produced significant improvements in lung function compared to placebo, along with better symptom scores, less rescue inhaler use, and fewer nighttime awakenings.1PubMed. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma The improvements in FEV1 (a standard measure of how much air you can forcefully exhale in one second) were roughly similar across all three doses, which suggests that for many people with milder disease, there is not a dramatic additional benefit from going higher.
Pediatric Doses
Children aged 4 to 11 are typically prescribed 40 to 160 mcg once daily. The RAINBOW study tested three doses (40, 80, and 160 mcg once daily) against placebo in children with persistent asthma and found that all three improved peak expiratory flow, asthma control, symptom scores, and quality of life, with side-effect rates comparable to placebo at roughly 35 percent across groups.2PubMed. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study The study also found no difference in outcomes between children who used a spacer and those who did not, which is a practical convenience for families.
Growth suppression is a persistent worry with any inhaled steroid in children. A year-long trial specifically designed to measure growth velocity found that children on ciclesonide 40 mcg grew at nearly the same rate as children on placebo, with a difference of just 0.02 cm per year. Even at 160 mcg, the difference was only 0.15 cm per year, and neither dose was statistically different from placebo. Overnight and 24-hour urine cortisol levels also remained unchanged.3PubMed. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma That growth-neutral profile is one reason some pediatric specialists favor Alvesco.
When ciclesonide 160 mcg once daily was compared head-to-head with budesonide 400 mcg once daily in children, the two inhalers produced equivalent improvements in lung function, symptoms, and quality of life. However, children on ciclesonide grew significantly more than those on budesonide, and their cortisol levels were less suppressed.4PubMed. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma These results matter for parents weighing long-term use of a controller inhaler in a growing child.
Why Alvesco Behaves Differently From Other Steroid Inhalers
Most inhaled corticosteroids are already pharmacologically active the moment they leave the canister. Alvesco is different. The ciclesonide you inhale is largely inactive until esterase enzymes in the cells lining your airways chop off a side chain, creating the active metabolite called desisobutyryl-ciclesonide (des-CIC). This conversion happens primarily in the bronchial tissue where you need the drug to work.5PubMed. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue Whatever ciclesonide gets swallowed (about half of any inhaled dose ends up in the throat and stomach) passes through the liver, where it is rapidly cleared before much of it can enter the bloodstream.6PubMed Central. Metabolism of ciclesonide in the upper and lower airways: review of available data
This targeted activation is why Alvesco can be dosed once daily and why its systemic side effects tend to be low even at higher doses. The drug does its job in the lungs and mostly avoids reaching the rest of the body in active form. That distinction matters for the dose conversation because it means the numbers on the label are not directly interchangeable with the numbers on a budesonide or fluticasone label.
Dose Equivalence With Other Inhaled Steroids
Comparing doses across different inhaled steroids is not as simple as matching microgram for microgram. A Cochrane review evaluating ciclesonide against other inhaled corticosteroids in both adults and children found that at equal daily microgram doses, ciclesonide and beclomethasone or budesonide produced similar peak flow results. At equal doses with fluticasone, lung function outcomes were also not significantly different.7Cochrane Database of Systematic Reviews. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
A separate Cochrane review focused on children found that at a dose ratio of one-to-two (for example, ciclesonide 160 mcg versus budesonide 320 mcg), asthma symptoms and exacerbation rates were similar, but cortisol suppression was significantly greater with budesonide. At a one-to-one ratio with fluticasone, symptoms and exacerbations were also similar, and cortisol levels did not differ between the two drugs. However, when ciclesonide was compared with fluticasone at half the fluticasone dose (a one-to-two ratio in favor of fluticasone), exacerbations were significantly more frequent with ciclesonide.8Cochrane Database of Systematic Reviews. Ciclesonide compared to budesonide and fluticasone in the treatment of asthma in children The practical takeaway: ciclesonide is roughly equivalent to fluticasone microgram-for-microgram, but can match budesonide at about half the budesonide dose. Your prescriber uses these ratios when switching you from one inhaler to another.
Stepping Down When Asthma Is Well Controlled
Asthma guidelines generally recommend trying to reduce your controller medication once symptoms have been stable for a few months. Because Alvesco is dosed once daily, it fits naturally into step-down strategies. In one trial, patients whose asthma was well controlled on fluticasone 250 mcg twice daily were either kept on that regimen or switched to ciclesonide 160 mcg once daily. Both groups maintained virtually identical asthma control: more than 97 percent of days with asthma under control, 98 percent symptom-free days, and 100 percent of days free from rescue medication use.9PubMed. Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma
Another trial looked at stepping down from a combination inhaler (steroid plus a long-acting bronchodilator) to a steroid-only inhaler. Patients switched to ciclesonide maintained more stable lung function than those switched to budesonide, even though the budesonide dose was higher in corticosteroid-equivalent terms. The ciclesonide group also reported higher adherence and satisfaction.10npj Primary Care Respiratory Medicine. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study Once-daily dosing likely helps with adherence: remembering one puff in the evening is easier than remembering two sessions a day.
One thing that does not appear to help is simply doubling your existing inhaler dose at the first sign of worsening symptoms. A Cochrane review of eight studies covering nearly 1,800 participants found that people who increased their inhaled steroid dose at the earliest signs of an exacerbation had about the same odds of needing rescue oral steroids as people who kept their dose the same.11PubMed Central. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children If your symptoms are flaring, calling your doctor is a better strategy than quietly adding extra puffs.
High-Dose Alvesco for Severe Asthma
For patients whose asthma is not well managed at standard doses, higher regimens have been studied. A trial comparing ciclesonide 160 mcg daily to 640 mcg daily in patients with severe asthma found that both doses meaningfully improved lung function. However, the 640 mcg group had fewer exacerbations (about 7 percent versus about 13 percent), significantly longer time to a first exacerbation, and greater improvements in peak flow and symptom scores. Importantly, even at 640 mcg per day, no significant changes in serum cortisol were observed.12PubMed. Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma
Separate research on patients experiencing actual asthma exacerbations found that high-dose ciclesonide produced rapid anti-inflammatory effects and clinical improvement with an acceptable safety profile.13PubMed Central. Efficacy of ciclesonide in the treatment of patients with asthma exacerbation These findings are relevant if your prescriber is considering whether to keep you on a moderate dose with add-on therapy or push the ciclesonide dose higher. The prodrug mechanism helps explain why cortisol suppression remains minimal even at these higher levels: the liver continues to clear any ciclesonide that escapes the lungs before it can become active systemically.
The Dose-Response Curve Is Relatively Flat
A pattern you may have noticed across these trials is that large increases in dose do not always translate to proportionally larger improvements in standard outcomes like FEV1. A crossover study that measured a different and more sensitive marker, airway responsiveness to adenosine monophosphate, did find a clear dose-dependent effect at 100, 400, and 1,600 mcg daily.14American Journal of Respiratory and Critical Care Medicine. A Dose-dependent Effect of the Novel Inhaled Corticosteroid Ciclesonide on Airway Responsiveness to Adenosine-5′-Monophosphate in Asthmatic Patients But in everyday clinical terms, the difference between 80 and 320 mcg on FEV1 is modest, as the trial of those three doses demonstrated.15PubMed. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma
This matters for you as a patient because it means most of the benefit is captured at the lower end of the dosing range. Going higher has the most value when asthma is severe enough that exacerbation prevention becomes the primary goal, as the 160-versus-640 trial showed. For mild-to-moderate disease, more is not dramatically better, and your prescriber is likely to keep you at the lowest effective dose.
Side Effects Across the Dose Range
Oral thrush (candidiasis) is the most common local side effect of inhaled steroids, and this is where Alvesco’s prodrug design pays off most visibly. Because ciclesonide is largely inactive when it deposits in the mouth and throat, it causes less irritation there. A Cochrane review comparing ciclesonide with other inhaled steroids found that candidiasis was significantly less frequent with ciclesonide, although other local side-effect measures did not show clear differences.16Cochrane Database of Systematic Reviews. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
A more recent review of 25 studies addressing local side effects found that most studies (15 of 25) showed no significant difference between ciclesonide and comparator steroids, but seven studies did find a reduced risk of local adverse effects with ciclesonide. One observational study was an outlier, finding more oropharyngeal candidiasis treatment in ciclesonide users, though observational studies carry more potential for confounding than randomized trials.17PubMed. Local and systemic adverse effects of inhaled corticosteroids – Does ciclesonide differ from other inhaled corticosteroids?
On the systemic side, cortisol suppression is the worry that matters most over time. A four-week study in adults with moderate-to-severe asthma tested ciclesonide at 640 and 1,280 mcg daily alongside fluticasone 880 mcg daily. None of the treatments significantly affected 24-hour serum cortisol or the response to a cortisol stimulation test compared to placebo. Interestingly, the 640 mcg ciclesonide group actually showed a slight increase in urinary cortisol, essentially the opposite of suppression.18PubMed. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma These results are reassuring for patients who need higher doses long-term.
Spacers, Technique, and Getting the Dose Right
Alvesco is delivered as a pressurized metered-dose inhaler (pMDI), the standard “press and breathe” canister. A common question is whether you need a spacer (a hollow tube or chamber attached to the inhaler). A pharmacokinetic study found that using an AeroChamber Plus spacer did not change the amount of active metabolite reaching the bloodstream, indicating that lung deposition of ciclesonide was similar with and without the spacer.19PubMed. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation
That said, coordination between pressing the canister and breathing in is the single most common inhaler mistake. When inhalation is mistimed, the effective dose drops for both ciclesonide and fluticasone. But when a valved holding chamber was added and the patient inhaled at the moment of actuation rather than before it, the delivered dose of ciclesonide rebounded fully to the levels seen with correct technique. The chamber’s protective effect was especially strong for the very fine particles under 1 micrometer that reach the smallest airways.20PubMed Central. Optimizing Fluticasone Propionate and Ciclesonide pMDI Delivery: The Protective Role of Valved Holding Chambers Against Inhalation Timing Errors So while a spacer is not essential for getting the right dose with perfect technique, it acts as a safety net against poor coordination.
Alvesco’s formulation produces extrafine particles with a median aerodynamic diameter of about 1.0 micrometer, which is smaller than most other inhaled steroids. That small particle size allows it to deposit deeper in the lungs, reaching the peripheral airways where inflammation often persists in uncontrolled asthma.21PubMed Central. Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids Lab testing confirmed that without a spacer, throat deposition from ciclesonide was only about a quarter of the label dose, compared to roughly half for fluticasone, meaning less drug wasted in the mouth and more reaching the target tissue.22BMJ. In vitro characterisation of fluticasone propionate and ciclesonide delivered with and without valved holding chambers using cascade impaction and an adult simulated breathing profile
Off-Label Use During COVID-19
During the early months of the COVID-19 pandemic, ciclesonide attracted attention as a potential treatment for viral pneumonia. Japanese clinicians published a case series using Alvesco 200 mcg inhaled two to three times daily (two puffs each time) in patients with COVID-19 pneumonia, with some clinical improvement observed.23PubMed Central. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases A subsequent randomized trial in France (the COVERAGE study) formally tested inhaled ciclesonide among outpatients with COVID-19 who had risk factors for worsening, though results from that arm were mixed and ciclesonide did not become a standard COVID-19 treatment.24PubMed Central. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE) The episode is worth knowing about mainly because patients who search for Alvesco dosing information may encounter COVID-era protocols that bear no relation to how the drug is actually used for asthma management.
Timing and Practical Dosing Tips
Alvesco can be taken in the morning or evening, and trials have used both schedules. Evening dosing aligns with the natural circadian pattern of airway inflammation, which tends to peak in the early morning hours, but the clinical trials did not show a dramatic difference between the two. Pick whichever time you are most likely to remember consistently.
Unlike some other inhalers, Alvesco does not need to be shaken before use (it uses a solution-based formulation rather than a suspension). You should prime the inhaler with three test sprays before using it for the first time, or if you have not used it in more than ten days. The canister should be at room temperature; cold canisters deliver less drug per puff. After inhaling, there is no strong need to rinse your mouth the way there is with budesonide or fluticasone, because very little active drug sits on the oral tissues. Some clinicians still recommend rinsing out of habit, and it certainly does no harm, but the lower candidiasis rate with ciclesonide makes it less of a necessity than with other inhaled steroids.
If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose. Do not double up. Because ciclesonide’s active metabolite also gets stored as a fatty acid conjugate inside lung cells and released slowly, a single missed dose is less disruptive than it might be with a shorter-acting steroid, though this is not an excuse to skip doses routinely.